1
|
Qin X, Gao X, Yang Y, Ou S, Luo J, Wei H, Jiang Q. Developing a risk assessment tool for cancer-related venous thrombosis in China: a modified Delphi-analytic hierarchy process study. BMC Cancer 2024; 24:120. [PMID: 38263026 PMCID: PMC10807161 DOI: 10.1186/s12885-024-11877-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2023] [Accepted: 01/13/2024] [Indexed: 01/25/2024] Open
Abstract
OBJECTIVE To develop a Risk Assessment Tool for Cancer-related Venous Thrombosis in China. METHODS A modified two-round Delphi method was employed to establish consensus within a field to reach an agreement via a questionnaire or by interviewing a multidisciplinary panel of experts by collecting their feedback to inform the next round, exchanging their knowledge, experience, and opinions anonymously, and resolving uncertainties. Furthermore, The AHP (Analytic Hierarchy Process) was used to determine the final quality indicators' relative importance. RESULTS The expert's positive coefficient was 85.19% in the first round and 82.61% in the second round, with authoritative coefficients of 0.89 and 0.92 in the respective surveys. The P-value of Kendall's W test was all less than 0.001 for each round, and the W-value for concordance at the end of the two rounds was 0.115. The final Risk Assessment Tool for Cancer-related Venous Thrombosis consisted of three domains, ten subdomains, and 39 indicators, with patient factors weighing 0.1976, disease factors weighing 0.4905, and therapeutic factors weighing 0.3119. CONCLUSION The tool is significantly valid and reliable with a strong authority and coordination degree, and it can be used to assess the risk of cancer-related VTE and initiate appropriate thrombophylactic interventions in China.
Collapse
Affiliation(s)
- Xiaoli Qin
- Department of Pharmacy, The Third People's Hospital of Chengdu, 610031, Chengdu, Sichuan, P.R. China
- School of Pharmacy, Chengdu Medical College, 610500, Chengdu, Sichuan, P.R. China
| | - Xiurong Gao
- School of Pharmacy, Chengdu Medical College, 610500, Chengdu, Sichuan, P.R. China
| | - Yujie Yang
- Department of Pharmacy, The Third People's Hospital of Chengdu, 610031, Chengdu, Sichuan, P.R. China
| | - Shunlong Ou
- Department of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, 610041, Chengdu, Sichuan, P.R. China
| | - Jing Luo
- Department of Pharmacy, The Second People's Hospital of Yibin, 644000, Yibin, Sichuan, P.R. China
| | - Hua Wei
- Department of Pharmacy, Chengdu Second People's Hospital, 610011, Chengdu, Sichuan, P.R. China
| | - Qian Jiang
- Department of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, 610041, Chengdu, Sichuan, P.R. China.
| |
Collapse
|
2
|
Luo J, Ou S, Wei H, Qin X, Peng R, Wang S, Jiang Q. Value assessment of NMPA-approved new cancer drugs for solid cancer in China, 2016-2020. Front Public Health 2023; 11:1109668. [PMID: 36908440 PMCID: PMC9998930 DOI: 10.3389/fpubh.2023.1109668] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2022] [Accepted: 02/09/2023] [Indexed: 02/26/2023] Open
Abstract
Background Whether the high cost of cancer drugs is commensurate with their value to patients, which has become the focus of public concern. We aimed to assess the value of new cancer drugs approved for solid cancer in China and to explore the association between price and value of drugs. Methods We identified all new drugs for solid tumor that approved by the China's National Medical Products Administration (NMPA) between 2016 and 2020. The value of these drugs was assessed according to the American Society of Clinical Oncology Value Framework (ASCO-VF) and the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). We calculated Cohen's κ statistic to describe agreement between the two frameworks. Spearman's correlation coefficient was used to evaluate the correlation between price and value of drugs. Results Between 2016 and 2020, 37 new drugs were approved by the NMPA for solid tumor and we could evaluate the value of 28 drugs (76%). Eight (29%) of drugs were approved for non-small-cell lung cancer and 6 (21%) for breast cancer. ASCO-VF scores had a range of -20 to 110.1, and the median score was 43.3 (inter-quartile range 27.1-58.35). Only seven drugs (25%) met the ASCO-VF cutoff score. By the ESMO-MCBS, 13 drugs showed a meaningful value. Agreement between these two frameworks thresholds was only fair (κ = 0.515, P < 0.05). We found no statistically significant correlation between launch price of drugs and clinical benefit according to both frameworks. Conclusions Not all NMPA-approved new cancer drugs had meaningful value as measured by ASCO-VF or ESMO-MCBS. There was no significant correlation between drug price and the level of clinical benefit.
Collapse
Affiliation(s)
- Jing Luo
- School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China
| | - Shunlong Ou
- Department of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan, China
| | - Hua Wei
- Department of Pharmacy, Chengdu Second People's Hospital, Chengdu, Sichuan, China
| | - Xiaoli Qin
- Department of Pharmacy, The Third People's Hospital of Chengdu, Chengdu, Sichuan, China
| | - Rui Peng
- Department of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan, China
| | - Song Wang
- Department of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan, China
| | - Qian Jiang
- Department of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, Sichuan, China
| |
Collapse
|
3
|
Luo J, Ou S, Wei H, Qin X, Jiang Q. Comparative Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Ovarian Cancer: A Systematic Review and Network Meta-Analysis. Front Oncol 2022; 12:815265. [PMID: 35756600 PMCID: PMC9213680 DOI: 10.3389/fonc.2022.815265] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2022] [Accepted: 05/17/2022] [Indexed: 11/24/2022] Open
Abstract
Objective This study aims to compare the efficacy and safety of different poly (ADP-ribose) polymerase (PARP) inhibitors in patients with ovarian cancer through a network meta-analysis to support clinical treatment choices. Methods The Cochrane Library, PubMed, Embase, Science Citation Index, China National Knowledge Infrastructure (CNKI), Wanfang Data, Chongqing VIP (CQVIP), and Chinese BioMedical Literature Database (CBM) were searched with a cutoff date of 14 January 2021. ClinicalTrials.gov was also checked for supplementary data. Phase II or III randomized controlled trials that compared a PARP inhibitor with a placebo in patients with relapsed or newly diagnosed advanced ovarian cancer were included. The hazard ratios (HRs) for progression-free survival and overall survival and odds ratios (ORs) for grade 3 or higher adverse events were analyzed. The network meta-analysis was conducted in a Bayesian framework based on the Markov Chain Monte Carlo model in the R gemtc package (version 4.0.3). Results Eight eligible articles reporting six trials with a total of 2,801 patients were incorporated in this network meta-analysis. Three trials compared olaparib with placebo. Two trials compared niraparib with placebo. One trial compared rucaparib with placebo. The network meta-analysis failed to show significant differences in progression-free survival among the three PARP inhibitors: HR of 0.64, 95% confidence interval of 0.3 to 1.42 for olaparib versus niraparib, and olaparib versus rucaparib (0.86; 0.33 to 2.33). The comparison between niraparib and rucaparib also did not express a statistical difference (1.34; 0.47 to 3.72). Subgroup analysis bybreast cancer susceptibility gene (BRCA) status showed no obvious difference in progression-free survival among the three PARP inhibitors regardless of BRCA mutation status. Olaparib had fewer grade 3 or higher adverse events than niraparib (OR, 0.27; 95% confidence interval, 0.13 to 0.55) and rucaparib (0.34; 0.14 to 0.86). However, the analysis failed to show a significant difference between niraparib and rucaparib (1.27; 0.49 to 3.27). Conclusion Current evidence indicates that there is no significant difference observed in efficacy among olaparib, niraparib, and rucaparib. However, olaparib might have fewer grade 3 or higher adverse events.
Collapse
Affiliation(s)
- Jing Luo
- School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
| | - Shunlong Ou
- Sichuan Cancer Hospital & Institute, Sichuan Cancer Centre, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
| | - Hua Wei
- Department of Pharmacy, Dujiangyan People's Hospital, Dujiangyan Medical Center, Dujiangyan, China
| | - Xiaoli Qin
- School of Pharmacy, Chengdu Medical College, Chengdu, China
| | - Qian Jiang
- Sichuan Cancer Hospital & Institute, Sichuan Cancer Centre, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
| |
Collapse
|
4
|
Boyd C, Ou S, Long S, Stitzlein R, Abi-Jaoudeh N. Abstract No. 578 Bone and soft tissue ablation of painful thoracic metastasis: single center review of palliative ablation of metastatic rib and intercostal lesions. J Vasc Interv Radiol 2022. [DOI: 10.1016/j.jvir.2022.03.560] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
5
|
Lin HM, Yin Y, Curran E, Crossland V, Wu Y, Ou S. EGFR testing patterns and detection of EGFR exon 20 insertions among patients with NSCLC in the US. Am J Clin Pathol 2021. [DOI: 10.1093/ajcp/aqab191.304] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Introduction/Objective
Epidermal growth factor receptor (EGFR) mutations are common in non-small cell lung cancer (NSCLC). EGFR exon 20 insertions (EGFRex20ins), a rare subset of EGFR mutations, are refractory to tyrosine kinase inhibitors. With the development of targeted therapies for EGFRex20ins, such as mobocertinib, molecular testing is required to optimize treatment. A better understanding of real-world EGFR detection patterns is needed to maximize patient outcomes.
Methods/Case Report
This retrospective study describes EGFR testing and EGFRex20ins detection patterns in patients with NSCLC in the United States. The Flatiron Health electronic health record database was used to identify patients ≥18 years, with advanced NSCLC, and with ≥2 clinic visits between 01/01/2011 and 12/31/2020. Baseline demographics, clinical characteristics, EGFR testing, and EGFRex20ins detection rates by sex, race, and smoking history were summarized.
Results (if a Case Study enter NA)
A total of 67,281 patients with NSCLC were identified. EGFR testing increased from 44% in 2011 to 77% in 2020. Of all patients, 44,926 (66.8%) were tested: 50.8% female; 3.3% Asian; 16.0% never-smokers. Of all patients, 22,355 (33.2%) were not tested: 41.4% female; 1.2% Asian; 7.5% never-smokers. Of those tested, 6,245 (13.9%) patients had EGFR mutations: 65.9% female; 11.8% Asian; 48.4% never-smokers.
EGFRex20ins detection rates changed from 0.6% in 2011 to 1.0% in 2019 and 0.7% in 2020. Of those tested, 304 patients had EGFRex20ins: 58.2% female; 8.2% Asian; 50.3% never-smokers. EGFR testing was higher in females (71.2%) than males (62.8%), never-smokers (84.5%) than those with a smoking history (64.6%), and Asian patients (84.2%) than White (66.6%), Black (65.4%), or other patients (69.5%). Of those tested, EGFRex20ins mutations were detected in 0.8% of females (males: 0.6%), 2.2% of never-smokers (with smoking history: 0.4%), and 1.7% of Asians (White: 0.6%, Black: 0.6%, other patients: 0.7%) had EGFRex20ins. A similar trend was observed for EGFR mutations with higher proportions of females, never-smokers, and Asian patients affected.
Conclusion
EGFR testing and EGFRex20ins detection rates have increased. However, not all patient subgroups were tested at the same rate and undertesting occurred in all subgroups. Further education of specialists diagnosing NSCLC is warranted to ensure all patients receive biomarker testing and benefit from emerging EGFRex20ins- targeted therapies.
Collapse
Affiliation(s)
- H M Lin
- Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, UNITED STATES
| | - Y Yin
- Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, UNITED STATES
| | - E Curran
- Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, UNITED STATES
| | - V Crossland
- Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, UNITED STATES
| | - Y Wu
- Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, UNITED STATES
| | - S Ou
- The University of California, Irvine School of Medicine, Orange, California, UNITED STATES
| |
Collapse
|
6
|
Bazhenova L, Girard N, Minchom A, Ou S, Gadgeel S, Trigo J, Viteri S, Londhe A, Mahadevia P, Bauml J. P08.04 Comparative Clinical Outcomes Between EGFR Exon20ins and Wildtype NSCLC Treated with Immune Checkpoint Inhibitors. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
7
|
Gregory J, Kilvert H, Williams T, Cooper M, Polli A, Iadeluca L, Ou S. P08.02 Lorlatinib in First Line Treatment of Patients With ALK-Positive NSCLC: A Network Meta-Analysis. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
8
|
Lee J, Rosenzweig M, Piper-Vallillo A, Vanderlaan P, Tolba K, Li T, Riess J, Venstrom J, Oxnard G, Schrock A, Costa D, Ou S. MA02.03 MET-Driven Acquired Resistance (AR) in Fusion-Positive Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
9
|
Nagasaka M, Goto K, Gomez J, Hida T, Shu C, Lee C, Park K, Cho B, Lee J, Ou S, Bestvina C, Natale R, Haddish-Berhane N, Bhattacharya A, Verheijen R, Agrawal T, Knoblauch R, Govindan R. P50.04 Amivantamab in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
10
|
Lin H, Yin Y, Crossland V, Wu Y, Ou S. P37.31 Trends in the Detection of EGFR Exon 20 Insertions in Patients with NSCLC in the US. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.777] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
11
|
Girard N, Bazhenova L, Minchom A, Ou S, Gadgeel S, Trigo J, Viteri S, Li G, Mahadevia P, Londhe A, Backenroth D, Li T, Bauml J. MA04.07 Comparative Clinical Outcomes for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutations and Common EGFR Mutations. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.228] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
12
|
Chen J, Bearz A, Kim D, Mamdani H, Bauman J, Chiari R, Ou S, Solomon B, Soo R, Felip E, Shaw A, Clancy J, Lee K, O'Gorman M, Tanski C, Pithavala Y. P1.01-84 Interaction of Lorlatinib with CYP2B6, CYP2C9, UGT, and P-gp Probe Drugs in Patients with Advanced Non-Small Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.799] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
13
|
Ou S, Schrock A, Bocharov E, Lee J, Madison R, Gay L, Miller V, Alexander B, Husain H, Riess J, Ali S, Velcheti V. P1.01-86 Occurrence of de Novo Dual HER2/HER3 or HER2/EGFR TMD Mutations: Extending the Spectrum of Targetable Mono-HER2 TMD in NSCLC? J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
14
|
Ou S. ES18.04 New Strategies to Overcome Resistance in ALK Rearranged NSCLC. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
15
|
Le X, Zhu V, Saltos A, Nikolinakos P, Mileham K, Velcheti V, Husain H, Nilsson M, Tran H, Roarty E, Kim E, Ou S, Sanborn R, Gray J, Wong K, Hanna N, Papadimitrakopoulou V, Heymach J. P2.14-24 An Open-Label Randomized Phase II Study of Combining Osimertinib With and Without Ramucirumab in TKI-Naïve EGFR-Mutant Metastatic NSCLC. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1809] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
16
|
Hemmerich A, Madison R, Klempner S, Sokol E, Severson E, Miller V, Lee J, Ou S, Alexander B, Schrock A, Ross J, Ali S. Genomic profiling of diffuse gastric carcinoma (DGC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz154.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
17
|
Guo L, Ou S, Ma X, Zhang S, Lai Y. MACC1 silencing inhibits cell proliferation and induces cell apoptosis of lung adenocarcinoma cells through the β-catenin pathway. Neoplasma 2019; 65:552-560. [PMID: 29940751 DOI: 10.4149/neo_2018_170918n595] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
It has been documented that over-expression of metastasis-associated in colon cancer-1 (MACC1) is related to poor prognosis in non-small cell lung cancer (NSCLC). This study investigates the function and underlying molecular mechanisms of MACC1 in lung adenocarcinoma. Here, we firstly employed immunohistochemistry, western blotting, real-time PCR, and online database to demonstrate that MACC1 expression was elevated in tumor tissues compared with tumoradjacent or normal tissues. Real-time PCR, CCK-8, colony formation western blotting, Hoechst staining, and flow cytometry assays then evaluated the effects of MACC1 knockdown on the cell cycle, cell proliferation and apoptosis in A549 and H1299 adenocarcinoma cells. Result highlighted that MACC1 knockdown inhibited cell proliferation, induced G0/ G1 phase arrest and promoted cell apoptosis in vitro. Mechanistic analysis revealed it also up-regulated expression levels of bax, cleaved-caspase-3 and cleaved-PARP while down-regulating cyclin D1, c-myc, bcl-2, and β-catenin expression in A549 cells. Intriguingly, up-regulation of β-catenin suppressed G0/G1 phase arrest and apoptosis in MACC1-silenced A549 cells and this was accompanied by increased levels of cyclin D1, c-myc, and bcl-2. Collectively, our results indicate that MACC1 knockdown effectively inhibited cell proliferation and promoted apoptosis of lung adenocarcinoma cells by regulating the β-catenin pathway.
Collapse
Affiliation(s)
- L Guo
- Department of Cardiothoracic Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing, China
| | - S Ou
- Department of Cardiothoracic Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing, China
| | - X Ma
- Department of Cardiothoracic Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing, China
| | - S Zhang
- Department of Cardiothoracic Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing, China
| | - Y Lai
- Department of Cardiothoracic Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing, China
| |
Collapse
|
18
|
Ou S, Cho B, Kim D, Drilon A, Lee J, Lin J, Zhu V, Ahn M, Camidge D, Stopatschinskaja SS, Liu J, Cui J, Hyman D, Doebele R, Shaw A. OA09 Preliminary Clinical Activity of Repotrectinib (TPX-0005) in Advanced ROS1 Fusion-Positive Non-Small Cell Lung Cancer. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.10.019] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
19
|
Xiao W, Qi T, He S, Li Z, Ou S, Zhang G, Liu X, Huang Z, Liang F. Low Wall Shear Stress Is Associated with Local Aneurysm Wall Enhancement on High-Resolution MR Vessel Wall Imaging. AJNR Am J Neuroradiol 2018; 39:2082-2087. [PMID: 30262645 DOI: 10.3174/ajnr.a5806] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2018] [Accepted: 07/30/2018] [Indexed: 01/30/2023]
Abstract
BACKGROUND AND PURPOSE Some retrospective studies have found that the aneurysm wall enhancement on high-resolution MR vessel wall postgadolinium T1WI has the potential to distinguish unstable aneurysms. This study aimed to identify hemodynamic characteristics that differ between the enhanced and nonenhanced areas of the aneurysm wall on high-resolution MR vessel wall postgadolinium T1WI. MATERIALS AND METHODS TOF-MRA and high-resolution MR vessel wall T1WI of 25 patients were fused to localize the enhanced area of the aneurysm wall. Using computational fluid dynamics, we studied the aneurysm models. Mean static pressure, mean wall shear stress, and oscillatory shear index were compared between the enhanced and nonenhanced areas. RESULTS The aneurysmal enhanced area had lower wall shear stress (P < .05) and a lower oscillatory shear index (P = .021) than the nonenhanced area. In addition, the whole aneurysm had lower wall shear stress (P < .05) and a higher oscillatory shear index (P = .007) than the parent artery. CONCLUSIONS This study suggests that there are hemodynamic differences between the enhanced and nonenhanced areas of the aneurysm wall on high-resolution MR vessel wall postgadolinium T1WI.
Collapse
Affiliation(s)
- W Xiao
- From the Departments of Neurosurgery (W.X.,T.Q., S.O., G.Z., X.L., Z.H., F.L.)
| | - T Qi
- From the Departments of Neurosurgery (W.X.,T.Q., S.O., G.Z., X.L., Z.H., F.L.)
| | - S He
- Radiology (S.H., Z.L.), The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
| | - Z Li
- Radiology (S.H., Z.L.), The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
| | - S Ou
- From the Departments of Neurosurgery (W.X.,T.Q., S.O., G.Z., X.L., Z.H., F.L.)
| | - G Zhang
- From the Departments of Neurosurgery (W.X.,T.Q., S.O., G.Z., X.L., Z.H., F.L.)
| | - X Liu
- From the Departments of Neurosurgery (W.X.,T.Q., S.O., G.Z., X.L., Z.H., F.L.)
| | - Z Huang
- From the Departments of Neurosurgery (W.X.,T.Q., S.O., G.Z., X.L., Z.H., F.L.)
| | - F Liang
- From the Departments of Neurosurgery (W.X.,T.Q., S.O., G.Z., X.L., Z.H., F.L.)
| |
Collapse
|
20
|
Lin J, Kim D, Drilon A, Doebele R, Lee J, Zhu V, Ahn M, Lim J, Stopatschinskaja S, Cui J, Hyman D, Camidge R, Ou S, Shaw A, Cho B. OA02.02 Safety and Preliminary Clinical Activity of Ropotrectinib (TPX-0005), a ROS1/TRK/ALK Inhibitor, in Advanced ROS1 Fusion-Positive NSCLC. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.240] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
21
|
Drilon A, Clark J, Weiss J, Ou S, Camidge D, Solomon B, Otterson G, Villaruz L, Riely G, Heist R, Shapiro G, Murphy D, Wang S, Usari T, Li S, Wilner K, Paik P. OA12.02 Updated Antitumor Activity of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.300] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
22
|
Schrock A, Pavlick D, Rosenzweig M, Erlich R, Albacker L, Frampton G, Ross J, Miller V, Ali S, Ou S. MA16.05 MET Kinase Domain Rearrangements (KDRE) in Non-Small Cell Lung Cancer (NSCLC) Identified Through Comprehensive Genomic Profiling (CGP). J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.451] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
23
|
Solomon B, Shaw A, Ou S, Besse B, Felip E, Bauer T, Soo R, Bearz A, Lin C, Clancy J, Abbattista A, Thurm H, Peltz G, Masters E, Martini J, James L, Seto T. OA 05.06 Phase 2 Study of Lorlatinib in Patients with Advanced ALK+/ROS1+ Non-Small-Cell Lung Cancer. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.351] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
24
|
Lin J, Zhu V, Yoda S, Yeap B, Jessop N, Schrock A, Dagogo-Jack I, Gowen K, Stephens P, Ross J, Ali S, Miller V, Gainor J, Hata A, Iafrate A, Ou S, Shaw A. MA 07.07 Clinical Outcomes and ALK Resistance Mutations in ALK+ Non-Small Cell Lung Cancer According to EML4-ALK Variant. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.508] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
25
|
Drilon A, Clark J, Weiss J, Ou S, Camidge D, Solomon B, Otterson G, Villaruz L, Riely G, Heist R, Shapiro G, Murphy D, Liu Y, Wang S, Usari T, Wilner K, Paik P. OA 12.06 Plasma Genomic Profiling and Outcomes of Patients with MET Exon 14-Altered NSCLCs Treated with Crizotinib on PROFILE 1001. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
26
|
Ou S, Jong Y, Ho C, Lee W, Lin K, Jones C. The natural history of type 1 spinal muscular atrophy in Taiwan. Neuromuscul Disord 2016. [DOI: 10.1016/j.nmd.2016.06.067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
27
|
Antonia S, Ou S, Khleif S, Brahmer J, Blake-Haskins A, Robbins P, Li X, Vasselli J, Rizvi N. Clinical Activity and Safety of Medi4736, an Anti-Programmed Cell Death-Ligand 1 (Pd-L1) Antibody, in Patients with Non-Small Cell Lung Cancer. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
28
|
Ou S, Liu GD, Zhou LS, Xia X, Bai SR, Li J, Cui J, Cheng JM, Li YM, Zhang XY, Gu JW. Bioinformatics analysis of gene expression profiles in the rat cerebral cortex following traumatic brain injury. Eur Rev Med Pharmacol Sci 2014; 18:101-107. [PMID: 24452950] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
BACKGROUND Traumatic brain injury (TBI) is a serious neurodisorder commonly caused by sports related events or violence. It is the leading cause of disability in people under 40. AIM In order to elucidate the molecular mechanism of the secondary injury after TBI. MATERIALS AND METHODS In this study, we downloaded gene expression profile on TBI model with sham controls for gene set enrichment analysis and pathway analysis. RESULTS At a q-value of 5%, 361 genes were up-regulated and 373 were down-regulated in samples obtained at 48 hours after TBI. Functional analyses revealed that steroid biosynthesis, cell cycle, metal ion transport, inflammation and apoptosis were significantly dysregulated during the late period after trauma. In addition, MAPK3 (mitogen-activated protein kinase 3), was identified as the hub node in the protein-protein interaction (PPI) network constructed by the differentially expressed genes (DEGs). CONCLUSIONS Further elucidation of genes and proteins in our study may reveal their potential as novel therapeutic targets.
Collapse
Affiliation(s)
- S Ou
- Department of Anesthesiology, 2Department of Neurosurgery, General Hospital of Chengdu Military Command, Chengdu, Sichuan, P.R. China.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Affiliation(s)
- R Sharma
- Division of Gastroenterology, University of Rochester Medical Center, Strong Memorial Hospital, Rochester, New York, USA.
| | | | | | | |
Collapse
|
30
|
Bang YJ, Ou S, Camidge D, Clark J, Wilner K, Tye L, Stephenson P, Varella-Garcia M, Iafrate A, Shaw A. Clinical Activity of Crizotinib in Advanced Non-Small-Cell Lung Cancer (NSCLC) Harboring ROS1 Gene Rearrangement. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32008-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
31
|
Kris M, Goldberg Z, Janne P, Kim D, Martins R, Mok T, O'Connell J, Ou S, Taylor I, Zhang H. Dacomitinib (PF-00299804), An Irreversible Pan-Her Tyrosine Kinase Inhibitor (TKI), For First-Line Treatment of EGFR-Mutant or Her2-Mutant or -Amplified Lung Cancers. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33849-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
32
|
Ou S, Giambrone J, Macklin K. Infectious laryngotracheitis vaccine virus detection in water lines and effectiveness of sanitizers for inactivating the virus. J APPL POULTRY RES 2011. [DOI: 10.3382/japr.2010-00300] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
|
33
|
Kwak E, Camidge D, Clark J, Shapiro G, Maki R, Ratain M, Solomon B, Bang Y, Ou S, Salgia R. G6 Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)72045-2] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
34
|
Kwak EL, Camidge DR, Clark J, Shapiro GI, Maki RG, Ratain MJ, Solomon B, Bang Y, Ou S, Salgia R. Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.3509] [Citation(s) in RCA: 88] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3509 Background: PF-02341066 (PF) is a selective, ATP-competitive, small molecule oral inhibitor of the c-Met/HGFR and ALK receptor tyrosine kinases that has not previously been tested in humans. A Phase 1 dose-escalation trial evaluating PF as an oral single agent was conducted to investigate safety, PK and PD in patients (pts) with advanced cancer (excluding leukemias). Methods: PF was administered under fasting conditions QD or BID on a continuous schedule to pts in successive dose-escalating cohorts at doses ranging from 50 mg QD to 300 mg BID. Pts with advanced cancer were enrolled in the study. Results: Thirty-seven pts were enrolled into the dose escalation part of the study. Tumor types included colorectal, pancreatic, sarcoma, ALCL and NSCLC. The MTD was 250 mg BID. Three DLTs were observed: grade 3 increase in ALT (1 pt at 200 mg QD) and grade 3 fatigue (2 pts at 300 mg BID). The most common AEs were nausea, emesis, fatigue and diarrhea. Nausea and emesis were independent of dose or duration of treatment. Mean AUC (30–57% CV) and Cmax (36–69% CV) increased proportionally with dose from 100 mg QD to 300 mg BID. The median terminal half-life was 46 hours. A 2- to 4-fold increase in the oral midazolam (MDZ) AUC was observed following 28-days of PF dosing at 100 mg QD (n = 3) and 300 mg BID (n = 2), respectively, suggesting PF to be an inhibitor of CYP3A. Ten pts have entered an enriched RP2D cohort of pts with tumors harboring c-Met amplification/gene mutation or ALK fusion genes. There has been 1 confirmed PR in a sarcoma pt with ALK rearrangement (inflammatory myofibroblastic tumor). Among 10 NSCLC pts whose tumors harbor EML4-ALK rearrangement, 1 pt has had a PR, 2 pts have achieved unconfirmed PR and 4 pts have had SD (3 have experienced reduction in tumor burden by ∼20% in measurable lesions and 1 has been treated for 28 weeks). Conclusions: The MTD of PF is 250 mg BID. The major AEs were fatigue or GI-related, and all AEs were manageable and reversible. There was no evidence of non-linear PK at PF doses >100 QD. Treatment with PF-02341066 resulted in promising clinical activity against tumors carrying activating ALK gene rearrangements. Further study of PF in pts with ALK-dependent tumors is warranted. [Table: see text]
Collapse
Affiliation(s)
- E. L. Kwak
- Massachusetts General Hospital Cancer Center, Boston, MA; University of Colorado Cancer Center, Aurora, CO; Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan-Kettering Cancer Center, New York, NY; The University of Chicago, Chicago, IL; Peter MacCallum Cancer Centre, East Melbourne, Australia; Seoul National University Hospital, Seoul, Republic of Korea; UC Irvine Medical Center, Orange, CA; University of Chicago Cancer Center, Chicago, IL
| | - D. R. Camidge
- Massachusetts General Hospital Cancer Center, Boston, MA; University of Colorado Cancer Center, Aurora, CO; Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan-Kettering Cancer Center, New York, NY; The University of Chicago, Chicago, IL; Peter MacCallum Cancer Centre, East Melbourne, Australia; Seoul National University Hospital, Seoul, Republic of Korea; UC Irvine Medical Center, Orange, CA; University of Chicago Cancer Center, Chicago, IL
| | - J. Clark
- Massachusetts General Hospital Cancer Center, Boston, MA; University of Colorado Cancer Center, Aurora, CO; Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan-Kettering Cancer Center, New York, NY; The University of Chicago, Chicago, IL; Peter MacCallum Cancer Centre, East Melbourne, Australia; Seoul National University Hospital, Seoul, Republic of Korea; UC Irvine Medical Center, Orange, CA; University of Chicago Cancer Center, Chicago, IL
| | - G. I. Shapiro
- Massachusetts General Hospital Cancer Center, Boston, MA; University of Colorado Cancer Center, Aurora, CO; Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan-Kettering Cancer Center, New York, NY; The University of Chicago, Chicago, IL; Peter MacCallum Cancer Centre, East Melbourne, Australia; Seoul National University Hospital, Seoul, Republic of Korea; UC Irvine Medical Center, Orange, CA; University of Chicago Cancer Center, Chicago, IL
| | - R. G. Maki
- Massachusetts General Hospital Cancer Center, Boston, MA; University of Colorado Cancer Center, Aurora, CO; Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan-Kettering Cancer Center, New York, NY; The University of Chicago, Chicago, IL; Peter MacCallum Cancer Centre, East Melbourne, Australia; Seoul National University Hospital, Seoul, Republic of Korea; UC Irvine Medical Center, Orange, CA; University of Chicago Cancer Center, Chicago, IL
| | - M. J. Ratain
- Massachusetts General Hospital Cancer Center, Boston, MA; University of Colorado Cancer Center, Aurora, CO; Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan-Kettering Cancer Center, New York, NY; The University of Chicago, Chicago, IL; Peter MacCallum Cancer Centre, East Melbourne, Australia; Seoul National University Hospital, Seoul, Republic of Korea; UC Irvine Medical Center, Orange, CA; University of Chicago Cancer Center, Chicago, IL
| | - B. Solomon
- Massachusetts General Hospital Cancer Center, Boston, MA; University of Colorado Cancer Center, Aurora, CO; Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan-Kettering Cancer Center, New York, NY; The University of Chicago, Chicago, IL; Peter MacCallum Cancer Centre, East Melbourne, Australia; Seoul National University Hospital, Seoul, Republic of Korea; UC Irvine Medical Center, Orange, CA; University of Chicago Cancer Center, Chicago, IL
| | - Y. Bang
- Massachusetts General Hospital Cancer Center, Boston, MA; University of Colorado Cancer Center, Aurora, CO; Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan-Kettering Cancer Center, New York, NY; The University of Chicago, Chicago, IL; Peter MacCallum Cancer Centre, East Melbourne, Australia; Seoul National University Hospital, Seoul, Republic of Korea; UC Irvine Medical Center, Orange, CA; University of Chicago Cancer Center, Chicago, IL
| | - S. Ou
- Massachusetts General Hospital Cancer Center, Boston, MA; University of Colorado Cancer Center, Aurora, CO; Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan-Kettering Cancer Center, New York, NY; The University of Chicago, Chicago, IL; Peter MacCallum Cancer Centre, East Melbourne, Australia; Seoul National University Hospital, Seoul, Republic of Korea; UC Irvine Medical Center, Orange, CA; University of Chicago Cancer Center, Chicago, IL
| | - R. Salgia
- Massachusetts General Hospital Cancer Center, Boston, MA; University of Colorado Cancer Center, Aurora, CO; Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan-Kettering Cancer Center, New York, NY; The University of Chicago, Chicago, IL; Peter MacCallum Cancer Centre, East Melbourne, Australia; Seoul National University Hospital, Seoul, Republic of Korea; UC Irvine Medical Center, Orange, CA; University of Chicago Cancer Center, Chicago, IL
| |
Collapse
|
35
|
Pawel JV, Larson T, Ou S, Limentani S, Sandler A, Vokes E, Kim S, Liau K, Bycott P, Olszanski A, Schiller J. Efficacy and safety of single-agent axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): a phase II trial. Pneumologie 2008. [DOI: 10.1055/s-2008-1074447] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
36
|
Zell JA, Ou S, Ziogas A, Anton-Culver H. Proposed staging system modifications for advanced bronchioloalveolar carcinoma supported with a population-based validation study. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.7559] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7559 Background: Concordant with surgical series, our prior analysis of US SEER data demonstrates improved survival for BAC patients with stage IIIB disease due to multiple lesions in the same lobe compared to other stage IIIB patients, and also for patients with ipsilateral multicentric BAC compared to those with distant metastasis. In order for the BAC staging system to accurately reflect survival for these distinct patient subsets, we propose a revised staging system for advanced BAC and validate this system using California Cancer Registry (CCR) data. Methods: A case-only analysis of incident BAC cases in CCR during 1999–2003 was conducted. Based on modeling from our prior SEER analysis, the T4 descriptor for multiple tumors in the same lobe was downstaged to T3, and the M1 descriptor for ipsilateral multicentric BAC was downstaged to T4. The primary outcome measured was overall survival (OS). OS univariate analyses were conducted using the Kaplan-Meier method; multivariate survival analyses were performed using Cox proportional hazards ratios. Results: 1909 incident cases of histologically-confirmed BAC were analyzed. Using the proposed criteria, 162 (25%) of the 654 advanced BAC cases were reclassified: 73 cases with multiple lesions in the same lobe as T3 (stage II T3N0M0 [n=53] or T3NXM0 [n=1], stage IIIA T3N1–2M0 [n=18], stage IIIB T3N3M0 [n=1]); 89 cases with ipsilateral intrapulmonary metastasis were reclassified as T4 (stage IIIB, T4N1- 3M0). Univariate OS analysis of this validation set reveals an improved fit for the proposed staging system compared to the existing staging system ( Table 1 ). Analysis by stage reveals improvement in this proposed prognostic model over the existing staging system on multivariate survival analysis after adjustment for relevant clinicopathologic variables ( Table ). Conclusions: Our proposed BAC staging system modifications more accurately reflect survival characteristics for this unique type of non-small-cell lung cancer. [Table: see text]
Collapse
Affiliation(s)
| | - S. Ou
- Univ of California, Orange, CA
| | | | | |
Collapse
|
37
|
Halabi S, Ou S, Vogelzang NJ, Scher H, Small EJ. A novel intermediate endpoint for predicting overall survival in men with metastatic castration-recurrent prostate cancer (CRPC). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.5113] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5113 Background: In this proposed study, we developed and validated a novel composite clinical benefit endpoint constructed from symptoms that have intrinsic clinical importance in 800 men with CRPC who were treated with front-line chemotherapy. Methods: Data from nine multimember trials (five phase II and four randomized phase III studies) conducted by the Cancer and Leukemia Group B (CALGB) from 1992–2004 were combined. Eligible patients had progressive adenocarcinoma of the prostate during androgen ablation (despite castrate testosterone levels), an ECOG performance status of 0–2, adequate hematologic, renal and hepatic functions. The tripartite composite clinical benefit endpoint (TCCBE) had three components: one based on disease progression (whether it be PSA, bone, or soft tissue progression), and the second based on weight loss (defined as at least 10% decline from baseline) or on performance status (PS) decline (by at least one level) to capture clinical deterioration. The third component was based on pain control and opioid analgesic use (no or yes). For a person to fall in the TCCBE “yes” category, at least two of the three components had to be recorded as no. For instance, if a patient at 3 months had no progression, no change in weight and did not use opioid analgesic, then he will be classified in the “yes” group and for the purpose of this analysis was considered as someone who achieved “clinical benefit”. The sample was randomly split into 526 (67%) and 274 (33%) men in the training and testing datasets, respectively. Results: From the training dataset, the median survival times in men who had and did not have clinical benefit were 20.9 months (95% confidence interval (CI) = 18.5–22.8) and 11.1 months (95% = 8.79–12.6, p- value<0.001). In the testing dataset, the median survival times in men with and without clinical benefit were 21.7 months (95% CI= 19.1–26.1) and 8.8 months (95% CI= 7.8–11.6) and in men. The hazard ratio (HR) for men with a clinical benefit compared to men without was 0.52 (95% CI= 0.43–0.62, P<0.001). Conclusions: The TCCBE is a statistically significant intermediate endpoint for predicting overall survival. Prospective validation of this endpoint is needed. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. Halabi
- Duke University Medical Center, Durham, NC; Nevada Cancer Institute, Las Vegas, NV; Memorial Sloan Kettering Cancer Center, New York, NY; University of California, San Francisco, CA
| | - S. Ou
- Duke University Medical Center, Durham, NC; Nevada Cancer Institute, Las Vegas, NV; Memorial Sloan Kettering Cancer Center, New York, NY; University of California, San Francisco, CA
| | - N. J. Vogelzang
- Duke University Medical Center, Durham, NC; Nevada Cancer Institute, Las Vegas, NV; Memorial Sloan Kettering Cancer Center, New York, NY; University of California, San Francisco, CA
| | - H. Scher
- Duke University Medical Center, Durham, NC; Nevada Cancer Institute, Las Vegas, NV; Memorial Sloan Kettering Cancer Center, New York, NY; University of California, San Francisco, CA
| | - E. J. Small
- Duke University Medical Center, Durham, NC; Nevada Cancer Institute, Las Vegas, NV; Memorial Sloan Kettering Cancer Center, New York, NY; University of California, San Francisco, CA
| |
Collapse
|
38
|
Halabi S, Ou S, Vogelzang NJ, Small EJ. An elevated body mass (BMI) index predicts for better clinical outcomes in men with metastatic hormone refractory prostate cancer (HRPC). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.4556] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4556 Background: Previous articles have reported that an elevated BMI was associated with an increased risk of biochemical failure in hormone sensitive patients. We asked the question as to whether an elevated BMI predicts for worst clinical outcomes, namely overall survival (OS) and prostate-cancer survival (PCS), among 1,216 men with HRPC. Methods: Patients were enrolled on eight clinical trials conducted by the Cancer and Leukemia Group B (CALGB). Eligible patients had progressive prostate cancer during androgen deprivation therapy (with documented castrate levels of testosterone), an ECOG performance status of 0–2, adequate hematologic, renal and hepatic function. We used the NIH definition to classify patients as: normal (<25 kg/m2), overweight (25–29 kg/m2 ), mildly obese (30–34 kg/m2), and moderately to severely obese (≥35 kg/m2). PCS was defined as the time from study entry to the time of death due to prostate cancer. The proportional hazards model was used to explore the prognostic significance of BMI in predicting OS and PCS. Results: The median BMI was 27.7 kg/m2 (inter-quartile range = 25.2–31.0 kg/m2 ). Twenty three percent (285/1216) of the patients had normal BMI, 46% (555/1216) were overweight, 23% (280/1216) were mildly obese, and 8% (96/1216) were moderately to severely obese. In multivariate analysis, adjusting for age, race, performance status, hemoglobin, PSA, LDH, alkaline phosphatase, testosterone, years since diagnosis, presence of visceral disease and Gleason scores, BMI was a statistically significant predictor of OS and PCS. Compared to normal men, the hazard ratios (HR) of overweight patients was 0.80 (95% CI = 0.69–0.93, p-value = 0.003), for mildly obese patients was 0.86 (95% CI = 0.72–1.02, p-value = 0.087) and for moderately to severely obese men it was 0.60 (95% CI = 0.47–0.78, p-value < 0.001). In addition, the HRs for PCS for overweight patients was 0.83 (95% CI = 0.70–0.97, p-value = 0.023), was 0.88 (95% CI = 0.72–1.06, p-value = 0.179) for mildly obese and for moderately to severely obese was 0.62 (95% CI = 0.47–0.81, p-value = 0.001) compared to men with normal BMI. Conclusions: Contrary to what was reported, these findings demonstrate an inverse relationship between BMI and clinical outcomes in men with HRPC. [Table: see text]
Collapse
Affiliation(s)
- S. Halabi
- Duke University Medical Center, Durham, NC; Nevada Cancer Institute, Las Vegas, NV; University of California, San Francisco, CA
| | - S. Ou
- Duke University Medical Center, Durham, NC; Nevada Cancer Institute, Las Vegas, NV; University of California, San Francisco, CA
| | - N. J. Vogelzang
- Duke University Medical Center, Durham, NC; Nevada Cancer Institute, Las Vegas, NV; University of California, San Francisco, CA
| | - E. J. Small
- Duke University Medical Center, Durham, NC; Nevada Cancer Institute, Las Vegas, NV; University of California, San Francisco, CA
| |
Collapse
|
39
|
Halabi S, Small EJ, Ou S, Vogelzang NJ. The impact of age on clinical outcomes in men with hormone refractory prostate cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.4622] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- S. Halabi
- Duke Univ Medcl Ctr, Durham, NC; Univ of CA San Francisco, San Francisco, CA; Nevada Cancer Institute, Las Vegas, NV
| | - E. J. Small
- Duke Univ Medcl Ctr, Durham, NC; Univ of CA San Francisco, San Francisco, CA; Nevada Cancer Institute, Las Vegas, NV
| | - S. Ou
- Duke Univ Medcl Ctr, Durham, NC; Univ of CA San Francisco, San Francisco, CA; Nevada Cancer Institute, Las Vegas, NV
| | - N. J. Vogelzang
- Duke Univ Medcl Ctr, Durham, NC; Univ of CA San Francisco, San Francisco, CA; Nevada Cancer Institute, Las Vegas, NV
| |
Collapse
|
40
|
Regentin R, Cadapan L, Ou S, Zavala S, Licari P. Production of a novel FK520 analog in Streptomyces hygroscopicus: improving titer while minimizing impurities. J Ind Microbiol Biotechnol 2002; 28:12-6. [PMID: 11938465 DOI: 10.1038/sj/jim/7000208] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2001] [Accepted: 08/26/2001] [Indexed: 11/09/2022]
Abstract
FK520, also called ascomycin, is an immunosuppressive agent produced by Streptomyces hygroscopicus. Engineering the polyketide synthase genes of the parent strain generated novel FK520 analogs with the potential for improved in vivo stability. By replacing the acyl transferase (AT) domain in the polyketide synthase module 8 with an AT specific for methylmalonyl CoA (the rapamycin AT 3), the strain produced 13-desmethoxy-13-methyl-FK520 (13dmmFK520). Process development and scale-up studies of this recombinant S. hygroscopicus strain producing 13dmmFK520 are described here. Production kinetics and compound stability in fermentation broth were significantly different compared to the native FK520. Fermentation of the new strain resulted in the synthesis of a contaminating substance that co-purified with the 13dmmFK520. To optimize 13dmmFK520 production and to facilitate purification, growth parameters and media development were examined. Although a medium was identified that increased product titers by ca. 300%, the ratio of impurity to product was doubled. Lower dissolved oxygen (20% compared to 50% and 80%) increased titers by 20% with no appreciable effect on the concentration of impurity. Increasing the fermentation pH from 6.0 to 6.5 did not change the 13dmmFK520 titer, but reduced the impurity-to-product ratio by approximately 450%.
Collapse
Affiliation(s)
- R Regentin
- Department of Process Science, Kosan Biosciences, 3832 Bay Center Place, Hayward, CA 94545, USA
| | | | | | | | | |
Collapse
|
41
|
Frykman S, Tsuruta H, Lau J, Regentin R, Ou S, Reeves C, Carney J, Santi D, Licari P. Modulation of epothilone analog production through media design. J Ind Microbiol Biotechnol 2002; 28:17-20. [PMID: 11938466 DOI: 10.1038/sj/jim/7000209] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2001] [Accepted: 09/03/2001] [Indexed: 11/08/2022]
Abstract
Recently, the epothilone polyketide synthase (PKS) was successfully introduced into a heterologous production host for the large-scale production of epothilone D. We have found that at least three other epothilones can also be produced as the major fermentation product of this recombinant strain by supplementation of specific substrates to the production media. Addition of acetate or propionate to the media results in modulation of the epothilone D:C ratio, whereas addition of L-serine with either acetate or propionate yields epothilone H(1) or H(2) as the major product. This strategy permits production of at least four novel epothilones by culturing a single host with a genetically modified epothilone PKS in various media.
Collapse
Affiliation(s)
- S Frykman
- Kosan Biosciences, Inc., 3832 Bay Center Place, Hayward, CA 94545, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Frykman S, Tsuruta H, Lau J, Regentin R, Ou S, Reeves C, Carney J, Santi D, Licari P. Modulation of epothilone analog production through media design. J Ind Microbiol Biotechnol 2002. [DOI: 10.1038/sj.jim.7000209] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
43
|
Regentin R, Cadapan L, Ou S, Zavala S, Licari P. Production of a novel FK520 analog in Streptomyces hygroscopicus: Improving titer while minimizing impurities. J Ind Microbiol Biotechnol 2002. [DOI: 10.1038/sj.jim.7000208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
44
|
Abstract
We produced eight anti-huntingtin (Htt) monoclonal antibodies (mAbs), several of which have novel binding patterns. Peptide array epitope mapping shows that mAbs MW1-6 specifically bind the polyQ domain of Htt exon 1. On Western blots of extracts from mutant Htt knock-in mouse brain and Huntington's disease lymphoblastoma cell lines, MW1-5 all strongly prefer to bind to the expanded polyQ repeat form of Htt, displaying no detectable binding to normal Htt. These results suggest that the polyQ domain can assume different conformations that are distinguishable by mAbs. This idea is supported by immunohistochemistry with wild type (WT) and mutant Htt transgenic mouse (R6) brains. Despite sharing the same epitope and binding preferences on Western blots, MW1-5 display distinct staining patterns. MW1 shows punctate cytoplasmic and neuropil staining, while MW2-5 strongly stain the neuronal Golgi complex. MW6, in contrast, stains neuronal somas and neuropil. In addition, despite their preference for mutant Htt on blots, none of these mAbs show enhanced staining of R6 brains over WT, and show no binding of the Htt-containing nuclear inclusions in R6 brains. This suggests that in its various subcellular locations, the polyQ domain of Htt either takes on different conformations and/or is differentially occluded by Htt binding proteins. In contrast to MW1-6, MW7, and 8 can differentiate transgenic from WT mice by staining nuclear inclusions in R6/2 brain; MW8 displays no detectable staining in WT brain and stains only inclusions in R6/2 brain. Epitope mapping reveals that MW7 and 8 specifically bind the polyP domains and amino acids 83-90, respectively. As with MW1-6, the epitopes for MW7 and 8 are differentially available in the various subcellular compartments where Htt is found.
Collapse
Affiliation(s)
- J Ko
- Biology Division, California Institute of Technology, Pasadena, CA 91125, USA
| | | | | |
Collapse
|
45
|
Lombó F, Pfeifer B, Leaf T, Ou S, Kim YS, Cane DE, Licari P, Khosla C. Enhancing the atom economy of polyketide biosynthetic processes through metabolic engineering. Biotechnol Prog 2001; 17:612-7. [PMID: 11485419 DOI: 10.1021/bp010045j] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Polyketides, a large family of bioactive natural products, are synthesized from building blocks derived from alpha-carboxylated Coenzyme A thioesters such as malonyl-CoA and (2S)-methylmalonyl-CoA. The productivity of polyketide fermentation processes in natural and heterologous hosts is frequently limited by the availability of these precursors in vivo. We describe a metabolic engineering strategy to enhance both the yield and volumetric productivity of polyketide biosynthesis. The genes matB and matC from Rhizobium trifolii encode a malonyl-CoA synthetase and a putative dicarboxylate transport protein, respectively. These proteins can directly convert exogenous malonate and methylmalonate into their corresponding CoA thioesters with an ATP requirement of 2 mol per mol of acyl-CoA produced. Heterologous expression of matBC in a recombinant strain of Streptomyces coelicolor that produces the macrolactone 6-deoxyerythronolide B results in a 300% enhancement of macrolactone titers. The unusual efficiency of the bioconversion is illustrated by the fact that approximately one-third of the methylmalonate units added to the fermentation medium are converted into macrolactones. The direct conversion of inexpensive feedstocks such as malonate and methylmalonate into polyketides represents the most carbon- and energy-efficient route to these high value natural products and has implications for cost-effective fermentation of numerous commercial and development-stage small molecules.
Collapse
Affiliation(s)
- F Lombó
- Departments of Chemical Engineering, Chemistry, and Biochemistry, Stanford University, Stanford, California 94305-5025, USA
| | | | | | | | | | | | | | | |
Collapse
|
46
|
Abstract
There have been many reports concerning the role of dietary fiber in lowering postprandial serum glucose, and the main mechanism was regarded as the viscosity of different dietary fibers in hampering diffusion of glucose and postponing absorption and digestion of carbohydrates. In this paper, two kinds of water-insoluble dietary fibers, water-insoluble dietary fiber of wheat bran and enzyme-resistant starch of maize amylose, and four kinds of water-soluble dietary fibers, water-soluble dietary fiber of wheat bran, carboxymethyl cellulose, guar gum, and xanthan gum, were used to investigate their postprandial serum glucose lowering mechanism in vitro. The results showed that these dietary fibers lowered postprandial serum glucose levels at least by three mechanisms. First, dietary fibers increase the viscosity of small intestine juice and hinder diffusion of glucose; second, they bind glucose and decrease the concentration of available glucose in the small intestine; and, third, they retard alpha-amylase action through capsuling starch and the enzyme and might directly inhibit the enzyme. All of these decreased the absorption rate of glucose and the concentration of postprandial serum glucose.
Collapse
Affiliation(s)
- S Ou
- Research Center of Food Science and Technology, Jinan University, Guangzhou 510632, People's Republic of China.
| | | | | | | |
Collapse
|
47
|
Kong LJ, Orozco BM, Roe JL, Nagar S, Ou S, Feiler HS, Durfee T, Miller AB, Gruissem W, Robertson D, Hanley-Bowdoin L. A geminivirus replication protein interacts with the retinoblastoma protein through a novel domain to determine symptoms and tissue specificity of infection in plants. EMBO J 2000; 19:3485-95. [PMID: 10880461 PMCID: PMC313951 DOI: 10.1093/emboj/19.13.3485] [Citation(s) in RCA: 148] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
Geminiviruses replicate in nuclei of mature plant cells after inducing the accumulation of host DNA replication machinery. Earlier studies showed that the viral replication factor, AL1, is sufficient for host induction and interacts with the cell cycle regulator, retinoblastoma (pRb). Unlike other DNA virus proteins, AL1 does not contain the pRb binding consensus, LXCXE, and interacts with plant pRb homo logues (pRBR) through a novel amino acid sequence. We mapped the pRBR binding domain of AL1 between amino acids 101 and 180 and identified two mutants that are differentially impacted for AL1-pRBR interactions. Plants infected with the E-N140 mutant, which is wild-type for pRBR binding, developed wild-type symptoms and accumulated viral DNA and AL1 protein in epidermal, mesophyll and vascular cells of mature leaves. Plants inoculated with the KEE146 mutant, which retains 16% pRBR binding activity, only developed chlorosis along the veins, and viral DNA, AL1 protein and the host DNA synthesis factor, proliferating cell nuclear antigen, were localized to vascular tissue. These results established the importance of AL1-pRBR interactions during geminivirus infection of plants.
Collapse
Affiliation(s)
- L J Kong
- Departments of Biochemistry and Botany, North Carolina State University, Raleigh, NC 27695, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Leaf T, Cadapan L, Carreras C, Regentin R, Ou S, Woo E, Ashley G, Licari P. Precursor-directed biosynthesis of 6-deoxyerythronolide B analogs in Streptomyces coelicolor: understanding precursor effects. Biotechnol Prog 2000; 16:553-6. [PMID: 10933827 DOI: 10.1021/bp000063l] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
A fermentation process employing precursor-directed biosynthesis is being developed for the manufacture of 6-deoxyerythronolide B (6-dEB) analogues. Through a plasmid-based system in Streptomyces coelicolor, 6-dEB synthesis is catalyzed by 6-dEB synthase (DEBS). 6-dEB synthesis is abolished by inactivation of the ketosynthase (KS) 1 domain of DEBS but can be restored by providing synthetic activated diketides. Because of its inherent catalytic flexibility, the KS1-deficient DEBS is capable of utilizing unnatural diketides to form various 13-substituted 6-dEBs. Here we characterize process variables associated with diketide feeding in shake-flask experiments. 13-R-6-dEB production was found to depend strongly on diketide feed concentrations, on the growth phase of cultures at feeding time, and on the R-group present in the diketide moiety. In all cases a major portion of the fed diketides was degraded by the cells.
Collapse
Affiliation(s)
- T Leaf
- Department of Process Science, Kosan Biosciences, Inc., 3832 Bay Center Place, Hayward, California 94545, USA
| | | | | | | | | | | | | | | |
Collapse
|
49
|
Nasu T, Ou S. Chlorpromazine at comparatively low concentrations potentiates carbachol-induced tonic contraction of ileal longitudinal smooth muscle of the guinea-pig. Fundam Clin Pharmacol 2000; 14:187-92. [PMID: 15602794 DOI: 10.1111/j.1472-8206.2000.tb00015.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The neuroleptic phenothiazine derivative chlorpromazine (CPZ) at high concentration (1 x 10(-5) M) decreased either the phasic or tonic contraction in response to carbachol and the carbachol-induced increase in [Ca2+]i in both phases in ileal muscle. In contrast, CPZ at low concentrations (8 x 10(-7) - 5 x 10(-6) M) decreased only the phasic contraction and potentiated the tonic contraction induced by carbachol. However, CPZ at these concentrations dose-dependently decreased the carbachol-induced increase in [Ca2+]i in both phases. These results suggested that CPZ dose-dependently decreased the initial phasic contraction in response to carbachol by inhibition of Ca2+ release from the intracellular storage sites. CPZ at low concentrations appears to increase Ca2+ sensitivity to contractile proteins in the carbachol-induced tonic phase. CPZ dose-dependently reduced the 60 mM K(+)-induced phasic and tonic responses and a concomitant decrease in [Ca2+]i in ileal muscle.
Collapse
Affiliation(s)
- T Nasu
- Department of Veterinary Pharmacology, Faculty of Agriculture, Yamaguchi University, Yamaguchi 753, Japan.
| | | |
Collapse
|
50
|
Chen J, Liu R, Han Q, Xia C, Luo J, Han J, Mei Y, Jian W, Ou S. [A preliminary study of two Chinese herbs protective tablets on some Chinese traditional medicines]. Zhong Yao Cai 1999; 22:566-9. [PMID: 12571894] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/28/2023]
Abstract
The protective action of 2 tablets of Chinese herb to 5 Chinese traditional medicines against harm of insects and mildews was tested. It was found that 2 tablets have a obvious effects of insect-repellency and mouthproof in the test with Homalomena occulta and Prunus armeniaca, the bore in the medicinal materials was decreased 94.95% and 95.55% respectively than that of check. The tablets have some effects of mildewproof in the test with Tussilago farfara.
Collapse
Affiliation(s)
- J Chen
- Zhongkai Agrotechnical College, GuanGzhou 510225
| | | | | | | | | | | | | | | | | |
Collapse
|